Pegylation of nanoliposomal paclitaxel enhances its efficacy in breast cancer

Tropical Journal of Pharmaceutical Research

Volumn 13, Issue 8, 2014, Pages 1195-1198

  Esfahani, Maedeh Koohi Moftakhari ^a   Alavi, Seyed Ebrahim ^a   Akbarzadeh, Azim ^b   Ghassemi, Soheil ^b   Saffari, Zahra ^b   Farahnak, Maryam ^b   Chiani, Mohsen ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Breast cancer; Cytotoxicity; Drug delivery; Nanoliposome; Paclitaxel; Pegylation

Indexed keywords

EID: 84906854252     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: 10.4314/tjpr.v13i8.1     Document Type: Article

References (18)

1. Guo J, Bourre L, Soden DM, O'Sullivan GC, O'Driscoll C. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics Biotechnol Adv. 2011; 29(4): 402-417.
2. Warner E. Clinical practice. Breast-cancer screening. N Engl J Med. 2011; 365(11): 1025-1032.
3. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009; 9 Suppl 2: S73-81.
4. American Cancer Society, Cancer Facts & Figures, America Cancer Society, Atlanta, GA, USA, 2011.
5. Sadjadi A, Nouraie M, Mohagheghi MA, Mousavi-Jarrahi A, Malekezadeh R, Parkin DM. Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev. 2005; 6(3): 359-363.
6. Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev. 2004; 5(1): 24-27.
7. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets. 2003; 3(3): 193-203.
8. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol. 1992; 19(6): 646-662.
9. Greco FA. Paclitaxel-based combination chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2001; 34(Suppl 4): S53-S56.
10. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995 Apr 13; 332(15): 1004-1014.
11. Dorr RT. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother. 1994; 28(5 Suppl): S11-S14.
12. Costantino L, Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov Today. 2012; 17(7-8): 367-378.
13. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther. 2001; 1(6): 923-947.
14. Latif N, Bachhawat BM. Liposomes in immunology. J. Biosci., Vol. 6, Number 4, 1984; pp. 491-502.
15. Georgens C, Weyermann J, Zimmer A. Recombinant virus like particles as drug delivery system. Curr Pharm Biotechnol. 2005; 6(1): 49-55.
16. Eliaz RE, Szoka FC Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001; 15; 61(6): 2592-2601.
17. Sharma G, Anabousi S, Ehrhardt C, Ravi Kumar MN. Liposomes as targeted drug delivery systems in the treatment of breast cancer. J Drug Target. 2006; 14(5): 301-310.
18. Giotta F, Lorusso V, Maiello E, Filippelli G, Valerio MR, Caruso M, Verderame F, Latorre A, Colucci G. Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. Ann Oncol. 2007; 18(Suppl 6): vi66-vi69.